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Introduction
　Many recent studies have investigated substances 
that are involved in the interaction between solid cancer 
cells and their induced ﬁ broblasts1‒6.  Among them, ba-
sic ﬁ broblast growth factor（FGF-2）was discovered by 
Gospodarowicz7 in 1974 as a protein that strongly pro-
motes the proliferation of ﬁ broblasts.  Later studies re-
ported its overexpression in highly malignant cancer 
cells, and malignant transformation of normal cells 
transfected with the FGF-2 gene8,9.  These results sug-
gest that FGF-2 is involved in the invasion of cancer 
cells and the proliferation of ﬁ broblasts around cancer 
cells in an autocrine or paracrine fashion ; however, the 
details are largely unknown.
　Previously, we reported that in an immunohistochem-
ical study of oral squamous cell carcinoma tissue, the 
expression or non-expression of FGF-2 in ﬁ broblasts 
was associated with cancer invasion and metastasis, 
and the prognosis10.
　In this study, we examined the effects of FGF-2 on 
cancer cell invasion and on ﬁ broblast proliferation in an 
in vitro model of invasion.
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Abstract : The aim of this study was to examine the effects of ﬁ broblast growth factor-2（FGF-2）on cancer 
cell invasion and on ﬁ broblast proliferation in an in vitro model of invasion.  Three kinds of human oral squa-
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oral squamous cell carcinoma cells by reverse transcriptase polymerase chain reaction（RT-PCR）.  Further-
more, recombinant human FGF-2（rhFGF-2）was reacted with each cell line, and the invasion rate was de-
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Material and methods
1. Cell lines and culture methods
　Three human oral squamous cell carcinoma cell lines 
with different invasive activities were used : OSC-20, 
OSC-19（lower invasive type）, and HOC313（higher 
invasive type）.  OSC-2011 is a cell line derived from a 
58-year-old female with metastatic tongue cancer to the 
cervical lymph nodes.  The mode of invasion12 was grade 
3.  OSC-1913 is derived from a 61-year-old male with 
metastatic tongue cancer to the cervical lymph nodes. 
The mode of invasion was grade 4C.  HOC31314 is de-
rived from a 51-year-old female with metastatic squa-
mous cell carcinoma（involving the mandibular gingiva 
and oral ﬂ oor）to the cervical lymph nodes.  The mode 
of invasion was grade 4D（higher invasive type）.  In 
addition, the normal ﬁ broblast line HGF-1（ATCC, VA, 
USA）, derived from the gingiva of a 28-year-old male, 
was used. Each cell line was cultured in Eagle’s mini-
mum essential medium（Eagle-MEM）（Nissui Phar-
maceutical Co., Tokyo, Japan）supplemented with 10% 
fetal bovine serum（FBS）（United Biotechnological, 
Victoria, Australia）and 2.5 mg/L of Fungizone（Bristol-
Myers, NY, USA）at 37℃ in an atmosphere of 5% CO2.
2. Western blot analysis
　A 500μL aliquot of M-PER（Pierce Biotechnology, 
Rockford, USA）was added to a culture of each cancer 
cell line and of ﬁ broblasts, and the culture supernatant 
was separated by centrifugation.  The concentration of 
protein in each supernatant sample was measured with 
a Bio-Rad Protein Assay kit（Bio-Rad, Hercules, CA, 
USA）, and FGF-2 and its high-affinity receptors 
FGFR-1 and FGFR-215 were detected by western blot-
ting.  After SDS-PAGE, proteins were transferred onto a 
PVDF membrane, which was blocked for 12 h with 5% 
skim milk phosphate-buffered saline（PBS）containing 
0.05% Tween 20.  The membrane was reacted for 1 h 
with a 1 :  200 PBS dilution of primary anti-FGF-2 poly-
clonal antibody SC-79（Santa Cruz Biotechnology, CA, 
USA）or anti-FGFR-1 polyclonal antibody SC-121（San-
ta Cruz Biotechnology, CA, USA）or anti-FGFR-2 poly-
clonal antibody SC-20735（Santa Cruz Biotechnology, 
CA, USA）, and subsequently with a 1 : 1,000 PBS dilu-
tion of secondary anti-rabbit IgG antibody NA934（Am-
ersham, Tokyo, Japan）for 1 h.  Protein expression was 
visualized with ECL-Western blotting detection re-
agents（Amersham International plc, Buckingham-
shire, UK）.  To analyze the expression of FGF-2 in each 
cancer cell culture supernatant, cells from each cell line, 
grown to conﬂ uence in a 100-mm tissue culture dish, 
were washed with PBS and cultured in serum-free Ea-
gle-MEM containing 0.1% BSA for a further 24 h.  The 
culture supernatant was separated by centrifugation, 
and FGF-2 was detected by western blotting.
3. Analysis of expression of FGF-2 and FGFRs 
mRNA
　The expression of FGF-2 and FGFRs mRNA was ex-
amined in cultured human oral squamous cell carcino-
ma cells by reverse transcriptase polymerase chain re-
action（RT-PCR）.  RNA was extracted from OSC-20, 
OSC-19, and HOC313 cells using an RNeasy Kit（QIA-
GEN KK, Tokyo, Japan）.  Single-strand cDNA was syn-
thesized from the RNA, and DNA was ampliﬁ ed by PCR 
with FGF-2- or FGFRs-speciﬁ c primers.  The PCR prod-
ucts were electrophoresed on agarose gels, and analyzed 
by photography under UV illumination.  The primers 
and PCR conditions used are shown in Table 1.
4. Fibroblast proliferation
　Fibroblast suspensions（3× 105 cells/ml）were pre-
Table 1　The primers and PCR conditions
Primer sequence
Size of target DNA fragment 
ampliﬁ ed by PCR
Annealing temperature
FGF-2
（5’）ATGGCAGCCGGGAGCATCACCCACG（3’）
（5’）TCAGCTCTTAGCAGACATTGGAAG（3’）
468 bp 63.8℃
FGFR-1
（5’）GGCAAAGAATTCAAACCTGAC（3’）
（5’）CATCACTGCCGGCCTCTCTTC（3’）
528 bp 62.3℃
FGFR-2
（5’）TCCACATGGAGATATGGAACAGGA（3’）
（5’）GGAGCTATTTATCCCCGAGTG（3’）
738 bp 63.4℃
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pared with serum-free Eagle-MEM containing 0.1% 
BSA and 0, 10, 50, 100, 500, or 1,000 ng/ml of recombi-
nant human FGF-2（rhFGF-2）（PEPRO TECH EC 
LTD., London, UK）.  Aliquots of 100 μL（3× 104 cells）
of these cell suspensions were placed in wells of 96-mi-
crowell plates, incubated at 37℃ in a 5% CO2 atmo-
sphere for 3 d, and reacted with the cell detection re-
agent（CellTiter96AQueous One Solution Reagent）. 
The proliferative activity of the cells was determined by 
their absorbance at 490 nm.
5. Invasion assay
　BD BioCoat Matrigel Invasion Chambers（8-μm 
pore-size PET membrane, 24 wells ; BD Biosciences, 
MA, USA）were used to assess the invasive ability of 
each cancer cell line.  Suspensions（5× 104 cells/ml）of 
each cancer cell line were prepared with serum-free Ea-
gle-MEM containing 0.1% BSA.  A 500μL suspension
（2.5× 104 cells）of each cancer cell line was placed in 
the upper chamber of an Invasion Chamber, 750μL of 
rhFGF-2（50 ng/ml）was added to the lower chamber, 
and the whole chamber was incubated at 37℃ in a 5% 
CO2 atmosphere for 24 h.  Under a light-microscope
（× 100 magniﬁ cation）, cells observed on the undersur-
face of the membrane were counted as invading cells.  A 
similar procedure was performed using a BD BioCoat 
Control Insert（8-μm pore-size, no ECM, 24 wells ; BD 
Biosciences）, and cells observed on the undersurface of 
the membrane were counted as migrating cells.  The in-
vasion rate16,17 of each cell line was calculated, and com-
pared with that of each cell line cultured in the absence 
of rhFGF-2.
6. Collagen gel invasion model
　Collagen gels were used as matrices for cancer cell in-
vasion, and prepared according to the method of Wren 
et al.18.  Type I collagen（Cellmatrix type I-A ; Nitta 
Gelatin Inc., Tokyo, Japan）, 10-fold concentrated 
EMEM, and reconstituting buffer（0.05 N NaOH solu-
tion containing 200 mM HEPES and 2.2% NaHCO3）
were mixed at a ratio of 8 : 1 : 1, and allowed to gel while 
enclosing 3× 106 ﬁ broblasts per ml.  Cancer cells（2×
106）from each cell line were overlaid on a collagen gel, 
and 3 ml of Recombinant Human FGF-2（rhFGF-2）
（50 ng/ml）in serum-free Eagle-MEM containing 0.1% 
BSA was added.  The cancer cells were cultured in sus-
pension at 37℃ in a 5% CO2 atmosphere for 21 d.  When 
the cell culture was completed, the rate of collagen gel 
contraction relative to the contraction of the control gel 
containing no rhFGF-2 was determined.  The collagen 
gel was ﬁ xed in 10% formalin, embedded in parafﬁ n, 
stained with hematoxylin and eosin by standard tech-
niques, and observed for cancer cell invasion.
7. Immunohistochemical examination
　Cancer cells（2× 106）from each cell line were over-
laid on a collagen gel, and 3 ml of FGF-2-neutralizing 
antibody（anti-FGF-2）（R & D Systems, MN, USA）
（5μg/ml）in 10% FBS-supplemented Eagle-MEM con-
taining rhFGF-2（50 ng/ml）was added.  The cancer 
cells were cultured in suspension at 37℃ in a 5% CO2 
atmosphere for 14 d.  Each specimen was ﬁ xed in 10% 
buffered formalin, and then embedded in parafﬁ n to 
prepare serial sections（4μm）.  After treating with 
trypsin solution for 30 min at 37℃ , immunohistochemi-
cal staining was performed by the Labeled Strept Avi-
din-Biotin method following deparafﬁ nization and rehy-
dration.  As a primary antibody, rabbit polyclonal anti-
bFGF antibody（SC-79）（× 100 dilution ; Santa Cruz 
Biotechnology, Santa Cruz, CA）was reacted at 4℃ for 
24 h.  The slides were incubated with biotinylated anti-
rabbit Ig（DACO, Kyoto, Japan）, and reacted at room 
temperature for 60 min.  After reacting with peroxidase-
conjugated streptoavidin（DACO）for 60 min, they 
were washed with PBS.  Immunohistochemical reac-
tions were developed in 3,3’-diaminobenzidine tetrahy-
drochloride（Wako, Osaka, Japan）, then counterstained 
with hematoxylin.
Results
1. Expression of FGF-2, FGFR-1 and FGFR-2
　Western blot analysis of FGF-2, FGFR-1 and FGFR-2 
proteins showed that the proteins were uniformly ex-
pressed in each cancer cell line and HGF-1.  The analy-
sis of FGF-2 protein in the culture supernatant of each 
cancer cell line revealed strong expression of FGF-2 pro-
tein in HOC313, but no expression of FGF-2 protein in 
the culture supernatant of HGF-1（Fig. 1）.
2. Expression of FGF-2 and FGFRs mRNA in cul-
tured human oral squamous cell carcinoma cells
　FGF-2 mRNA was expressed in all cancer cells. 
Among the FGFRs mRNA, FGFR-1 mRNA was ex-
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pressed weakly in OSC-20 and strongly in HOC313, 
whereas FGFR-2 mRNA was expressed to a similar de-
gree in all cancer cells（Fig. 2）.
3. Effects of FGF-2 on ﬁ broblast proliferation
　We examined the optimal concentration of rhFGF-2 
for ﬁ broblast proliferation by absorbance spectrometry, 
and found that the absorbance increased abruptly at 
the concentration of 50 ng/ml.  At rhFGF-2 concentra-
tions of 100, 500, and 1,000 ng/ml, the absorbance was 
almost constant at 0.875（Fig. 3）.
4. Effects of FGF-2 on cancer cell invasion
　We examined the effects of rhFGF-2（50 ng/ml）on 
the invasion of each cancer cell line, and found that the 
invasion rate was higher in the presence than in the ab-
sence of rhFGF-2.  In particular, the addition of rhF-
GF-2（50 ng/ml）signiﬁ cantly increased the invasion 
rate of OSC-19 from 0.56% to 7.4%（P＜ 0.05, Fig. 4）.
5. Contraction of collagen matrices
　When each cancer cell line was cultured in rhFGF-2-
containing medium, the collagen matrix markedly con-
tracted.  In particular, culture of OSC-20 cells resulted 
in contraction rates of 54.6% and 8.3% in the presence 
and absence（control）of rhFGF-2, respectively（P＜
0.05, Fig. 5）.
Fig. 1　Expression of FGF-2 and FGFRs in each cell line
FGF-2, FGFR-1 and FGFR-2 were uniformly expressed in each cell line. The analysis 
of FGF-2 in the culture supernatant of each cell line revealed strong expression of 
FGF-2 in HOC313, but no expression of FGF-2 in the culture supernatant of HGF-1.
Fig. 2　Reverse transcriptase polymerase chain reaction analysis of mRNA for FGF-2 and FGFRs
 FGF-2 : distinct band at 468bp was detected. FGFR-1 : distinct band at 528bp was detect-
ed. FGFR-2 : distinct band at 738bp was detected in OSC-20, OSC-19, HOC313. M: DNA 
size marker（100bp Ladder）.
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Fig. 4　Invasion rate of each cell line in the presence of FGF-2
A, B : Light-microscopic ﬁ ndings of the base surface of the Boyden Chamber after 
invasion assay by Giemsa stain. Invasion rate =（Number of invading cells/Number 
of migrating cells）× 100. The addition of rhFGF-2（50 ng/ml）signiﬁ cantly in-
creased the invasion rate of OSC-19 and HOC313（Mann-Whitney test）.
Fig. 3　Effects of FGF-2 on ﬁ broblast proliferation
The absorbance of ﬁ broblast cultures in the presence of 50 
ng/ml of rhFGF-2 markedly increased over that of ﬁ bro-
blast cultures in the absence of rhFGF-2.
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6. Cancer cell invasion in collagen matrices
　We observed the behavior of cancer cell invasion in 
the collagen gel invasion model in the presence or ab-
sence of the rhFGF-2.  In the presence of rhFGF-2, 
OSC-20 cells invaded in aggregates into the matrix ; 
OSC-19 cells extended projections in cords into the ma-
trix, and were in contact with many spindle-shaped ﬁ -
broblasts ; HOC313 cells were in contact with ﬁ bro-
blasts, and invaded diffusely（Fig. 6）.
7. Effects of anti-FGF-2 in collagen matrices
　The addition of anti-FGF-2 completely inhibited the 
invasion of OSC-20 and OSC-19 cells. Cancer cells and 
ﬁ broblasts were immunohistochemically examined for 
the expression of FGF-2 in a collagen gel invasion model 
containing anti-FGF-2 or no anti-FGF-2（control）. 
FGF-2 was expressed in cancer cells in both models, 
and in ﬁ broblasts accumulated at the invasive front of 
cancer cells in the control model.  However, no FGF-2 
expression was observed in ﬁ broblasts accumulated at 
the cancer invasive front in the anti-FGF-2-containing 
model（Fig. 7）.
Discussion
　The invasion of cancer cells is associated with tumor 
stromal ﬁ brosis19,20, and cancer cells are considered to 
Fig. 5　Contraction of collagen matrices
The rate of collagen gel contraction was small when cancer cells 
were cultured for 21 d in serum-free Eagle-MEM containing 
0.1% BSA, but markedly increased in the presence of rhFGF-2
（Mann-Whitney test）.
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interact with the ﬁ broblasts proliferating around cancer 
cells at the invasive front through cancer cell-produced 
factors, thereby promoting cancer cell proliferation and 
invasion.  It has been reported that cancer cells may 
produce several factors such as plasminogen activator 
and tumor-derived growth factor21 ; however, factors 
Fig. 6　Relationship between FGF-2 and Cancer cell invasion in colla-
gen matrices
 A : Co-culture of OSC-19 and ﬁ broblasts. No invasion of cancer 
cells occurred in serum-free Eagle-MEM containing 0.1% BSA
（H & E staining）. Scale bar indicates 100μm. B: Co-culture of 
OSC-19 and ﬁ broblasts in the presence of rhFGF-2. Cancer 
cells invaded toward ﬁ broblasts in the matrix（H & E stain-
ing）. Scale bar indicates 100 μm.
Fig. 7　Effects of anti-FGF-2 in collagen matrices
A: Co-culture of OSC-19 and ﬁ broblasts. There was expression of 
FGF-2 in cancer cells as well as ﬁ broblasts（arrow）. Scale bar indicates 
100μm. B: Co-culture of OSC-19 and ﬁ broblasts in the presence of an-
ti-FGF-2. The anti-FGF-2（5 μg/ml）inhibited the invasion of cancer 
cells. FGF-2 was expressed only in cancer cells, but not in ﬁ broblasts
（arrow）. Scale bar indicates 100μm.
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linking the proliferation and invasion of cancer cells to 
the proliferation of host ﬁ broblasts have not been clear-
ly identiﬁ ed, and their actions are largely unknown. 
Among the growth factors overexpressed in cancer 
cells22,23, ﬁ broblast growth-promoting FGF-2 was found 
to be strongly expressed in cancer cells and ﬁ broblasts 
at the invasive front in our previous immunohistochem-
ical study10.  Myoken et al.24 examined oral squamous 
cell carcinomas by immunohistochemical techniques, 
and reported stronger expression of FGF-2 than that in 
normal tissue, suggesting the possibility of its involve-
ment in malignant transformation and self-proliferation 
of cells.  Furthermore, additional studies have reported 
high expression of FGF-2 in human malignant tumor 
cell lines25,26, and that ﬁ broblasts transfected with 
FGF-2 cDNA underwent malignant transformation, ac-
quiring self-proliferative ability9.  Western blot analysis 
conﬁ rmed the expression of FGF-2, FGFR-1, and 
FGFR-2 proteins in three cancer cell lines with different 
modes of invasion.  FGF-2 was also detected in the cul-
ture supernatant of each cancer cell line, particularly in 
that of HOC313.  Since the culture supernatant of 
HGF-1 did not show expression of FGF-2, this result 
suggests that normal ﬁ broblasts do not secrete FGF-2 
extracellularly, unless they receive some stimulus.  Fur-
thermore, examination by RT-PCR of each cancer cell 
line for the expression of mRNA for FGF-2 and FGFRs 
showed strong expression of FGFR-1 mRNA in HOC313 
cells, suggesting that cancer cells with a higher invasive 
potential express higher levels of FGF-2 and its recep-
tors.  Schultz-Hector et al.27 and Kramer et al.28 report-
ed that the higher proliferative activity of oral squa-
mous cell carcinomas was associated with higher 
expression of FGF-2, which increased the production of 
cancer cell proteases, thereby enhancing cancer cell in-
vasive activity, suggesting an association between 
FGF-2 production and oral malignant tumor cell inva-
siveness.  Although FGF-2 has been reported to promote 
the invasion of OSC-20 and OSC-19（lower invasive 
type）only in the presence of ﬁ broblasts29, the invasion 
assay showed that the addition of rhFGF-2 promoted 
the invasiveness of cancer cells even in the absence of 
ﬁ broblasts.  In addition, the collagen gel invasion model 
of each cancer cell line showed a high rate of gel con-
traction in the presence of rhFGF-2, with prominent in-
vasion of cancer cells, suggesting that cancer cells pro-
duce FGF-2, which acts on them in an autocrine 
manner, thereby being involved in their invasiveness. 
On the other hand, we examined each cancer cell line 
for changes in invasive behavior following the addition 
of anti-FGF-2, and found that it completely inhibited 
the invasion of OSC-20 and OSC-19 cells.  In addition, 
immunohistochemical examination of FGF-2 expression 
showed that neutralization treatment with anti-FGF-2 
caused loss of FGF-2 expression in ﬁ broblasts accumu-
lated around cancer cells.  These ﬁ ndings suggest that 
the inhibition of ﬁ broblast proliferative activity reduces 
the invasiveness of cancer cells.  The results of this 
study indicate that FGF-2 produced by cancer cells pro-
motes their own invasion in an autocrine fashion, and 
simultaneously promotes the proliferation of the sur-
rounding ﬁ broblasts in a paracrine fashion ; thus, the 
interaction between cancer cells and ﬁ broblasts is in-
volved in the invasion of cancer cells.  Finally, a squa-
mous cell carcinoma cell line with higher invasive po-
tential showed higher expression of FGF-2, suggesting 
that the level of FGF-2 expression is an indicator of the 
degree of cancer malignancy.
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